Percutaneous aortic valve replacement: overview and suggestions for anesthestic management
Journal of Clinical Anesthesia (2010) 22, 373–378
Percutaneous aortic valve replacement: overview andsuggestions for anesthestic management☆
Hermann Heinze MD (Assistant Professor)a,⁎, Holger Sier MD, (Staff Cardiac Surgeon)b,Ulrich Schäfer MD (Senior Cardiologist)c, Matthias Heringlake MD, PhD (Professor)a
aDepartment of Anesthesiology, University of Lübeck, 23538 Lübeck, GermanybDepartment of Cardiothoracic Surgery, University of Lübeck, 23538 Lübeck, GermanycDepartment of Cardiology, Asklepios Klinik St. Georg, 20099 Hamburg, Germany
Received 29 December 2008; revised 22 April 2010; accepted 16 May 2010
Abstract Transcutaneous aortic valve replacement (AVR) is increasingly used for high-risk patients
with severe aortic stenosis, who have high operative mortality for surgical placement during
cardiopulmonary bypass (CPB). Retrograde transfemoral AVR is usually performed during sedation,
Aortic valve replacement;
whereas antegrade transapical AVR is done with general anesthesia. Both procedures can be carried out
without CPB. Extended hemodynamic monitoring, including pulmonary artery catheterization and
transesophageal echocardiography, may be useful. Transfemoral AVR requires placement of atransvenous right ventricular pacing lead. Typical complications include local bleeding, obstruction ofthe coronary ostia, and neurological insult due to embolization of sclerotic material. Aortic regurgitationdue to paravalvular leakage or inadequate device expansion also may occur. Renal function maydeteriorate on excessive application of contrast medium. Atrioventricular blocks may occur later ratherthan after conventional AVR which tend to occur immediately.
2010 Elsevier Inc. All rights reserved.
stenosis increasingly are elderly with significant comorbid-ities. As a result, AVR using conventional open-heart
Aortic valve replacement (AVR) is the treatment of
surgery with median sternotomy and cardiopulmonary
choice for patients with severe degenerative aortic stenosis,
bypass (CPB) may be associated with unacceptably high
offering both symptomatic relief and a potential for
mortality and morbidity in certain patients.
improved long-term survival. Patients presenting with aortic
Although most patients are treated for symptomatic and
critical aortic stenosis, less invasive procedures would bebeneficial. Intervention could be extended to patients for
whom the risk of surgical intervention is currently
Financial disclosure: Dr. U. Schäfer does consulting work and
receives honoraria from CRS™, CoreValve Inc, Irvine, CA, USA. Dr.
prohibitive . Possible steps to minimize perioperative
M. Heringlake receives scientific support and honoraria from Edwards
risk are to avoid sternotomy, CPB, and mechanical
Lifescience, Irvine, CA, USA and Covidien Healthcare, Mansfield,
ventilation. Therefore, alternative modes of valve replace-
ment strategies have been developed. After studies in
⁎ Corresponding author. Tel.: +49 (0) 451 500 4057; fax: +49 (0)451
animals in 2002 Cribier et al. were the first to implant
E-mail address: (H. Heinze).
a transcutaneous, catheter-mounted aortic valve using the
0952-8180/$ – see front matter 2010 Elsevier Inc. All rights reserved.
H. Heinze et al.
Mortality and morbidity rates reported for octogenarians undergoing isolated conventional transfemoral or transapical aortic
valve replacement (AVR)
Conventional isolated AVR
(For more information on the cause of the mortality and morbidity, the reader is referred to the specific literature.)MACE = Perioperative major adverse cardiovascular and cerebral events, including death from any cause, major arrhythmia, myocardial infarction,cardiac tamponade, stroke, urgent or emergent conversion to surgery, emergent percutaneous coronary intervention, cardiogenic shock, endocarditis, oraortic dissection.
antegrade transfemoral venous route . This approach is
AVR. Excellent results have been achieved with conven-
very challenging ; the retrograde arterial approach
tional isolated AVR in the last few years, with operative
then was introduced (ie, transfemoral-AVR and transa-
mortality rates of 5% to 10% noted in octogenarians
pical AVR ).
Mortality risk may increase excessively in the presence of
Initial results show at least comparable mid-term
additional factors. A strong link between operative mortality
morbidity and mortality rates to those with conventional
and the following predictive factors has been seen :
isolated AVR Accordingly, as numbers
advanced heart failure with severe left ventricular (LV)
increase , cardiac anesthesiologists will be confronted
dysfunction; comorbidities, eg, respiratory dysfunction,
with this patient group with increasing frequency. For
renal dysfunction, and peripheral or coronary arterial
both procedures, no CPB per se is needed; one may
atherosclerosis; and need for urgent surgery.
speculate that in the near future anesthesiologists with no
Beside "technical" inclusion criteria such as certain aortic
experience in cardiac anesthesia may be caring for
annulus and ascending aorta diameter a combina-
tion of risk factors or scoring systems also have been usedas inclusion criteria. There are no published guidelines forpatient selection, and percutaneous AVR remains investiga-
2. Technical aspects
tional . Therefore, patients presenting for percutaneousTF-AVR or TA-AVR are high-risk patients with highoperative mortality, and usually they have been refused for
Transcatheter AVR, especially transapical AVR, requires
a special operating room (OR). The so-called "hybrid OR"
Exclusion criteria include sepsis or acute endocarditis;
is a standard OR with an additional fluoroscopic
excessive femoral, iliac, or aortic atherosclerosis; calcifica-
angiography system equal to any standard catheterization
tion or tortuosity (for transfemoral AVR); aortic aneurysm;
laboratory. It combines all aspects of sterility needed for
bleeding diathesis or coagulopathy; recent myocardial
conventional surgery with the imaging techniques of a
infarction (MI) or cerebrovascular accident; mitral or
catheterization laboratory. Exellent imaging is required for
tricuspid valvular insufficiency (N grade II); LV or atrial
exact positioning of the valve. In the event of emergency
thrombus; uncontrolled atrial fibrillation; and previous aortic
conversion to conventional surgery, CPB should be readily
valve replacement. In addition, patients with echocardio-
available. Transfemoral AVR procedures are typically
graphic aortic valve annulus diameter b 20 mm or N 27 mm
performed in the catheterization laboratory. In the majority
and ascending aorta diameter N 45 mm were excluded
of cases, the anesthesiologist is confronted with limited space
. Some of these contraindications have been
in an unfamiliar surrounding.
abandoned For example, after evalution of thefeasibility of transapical valve-in-a-valve implantation inanimals , the first human case was reported There is
ongoing discussion as to whether certain valve malforma-tions such as biscupid aortic stenosis could be an exclusion
Aortic stenosis is the most common valvular heart disease
criterion, as stent deployment may be impaired .
and its prevalence is increasing with age . Approximately
During preoperative assessment, the anesthesiologist
2% to 5% of elderly individuals aged N75 years present with
should be especially aware of signs of severly reduced
signs of severe aortic stenosis and are scheduled for elective
LV systolic function, pulmonary arterial (PA) hypertension,
Anesthesia for percutaneous aortic valve replacement
respiratory dysfunction, especially chronic obstructive
6. Transfemoral aortic valve replacement
pulmonary disease, renal dysfunction or failure, and historyof neurological insult. In addition, many patients have
In the beginning, transfemoral AVR was commonly
had previous cardiac surgery and may be at increased risk
performed during general anesthesia . Since no CPB is
required, deep sedation is sufficient A combinationof propofol (0.3-1.5 to 3 mg/kg/hr) and remifentanil (1 to6 μg/kg/hr) works well. Currently there are no data available
comparing general anesthesia and deep sedation. Anindividualized approach is recommended.
Beside standard monitoring, invasive arterial and central
Premedication consists of aspirin, clopidogrel, and
venous blood pressures, no clear recommendations for
antibiotics for procedural prophylaxis. Aspirin (100 mg)
hemodynamic monitoring have been published. A PA
and clopidogrel (75 mg) are recommended for 6 months,
catheter for measuring PA pressure and mixed venous
with lifelong aspirin (100-300 mg) Placement of an
oxygen saturation may be used to detect ventricular
intravenous (IV) right ventricular pacing lead is mandatory
dysfunction and provide valuable data on global oxygen
and functionality should be tested before the procedure. A
balance As with conventional AVR, the decision to
transthoracic pacemaker is not recommended. Two methods
insert a PA catheter should be based on the comorbidities of
of transfemoral AVR have been published, but as antegrade
the individual patient.
transfemoral venous access carries the risk of injury to the
Transesophageal echocardiography (TEE) is extremely
mitral valve, retrograde transfemoral AVR is used nearly
helpful in determining acute changes in myocardial perfor-
exclusively. Vascular access is obtained either with or
mance during the procedure, to determine the position
without standard surgical cut-down of the subclavian artery,
and correct function of the prosthetic valve, and – most
external iliac artery, or common femoral artery. A stiff
important – to rule out residual aortic regurgitation and
guidewire is placed in retrograde fashion into the LV. Using
paravalvular leakages During transapical AVR per-
fluoroscopic guidance and rapid pacing (150-200 bpm) to
formed with general anesthesia, TEE should be included
minimize ventricular outflow, balloon dilatation of the
. Unfortunately, in patients undergoing transfemoral
stenotic valve is performed. After the balloon catheter is
AVR without general anesthesia, use of TEE during the
withdrawn again, the device is advanced and positioned
procedure is limited. In cases where TEE may not be used,
within the native valve. The CoreValve revalving system is a
intraoperative and postoperative transthoracic echocardiog-
self-expanding device and needs only additional balloon
raphy may help determine the etiology of hemodynamic
dilatation for modelling into the aortic root, while the
instability. As there is no access to the ascending aorta for
Edwards-Sapien valve has to be expanded actively during
epicardial echocardiography during both procedures, this
rapid pacing. After expansion correct positioning and
technique, which is helpful during conventional aortic
function is verified with fluoroscopic angiography and/or
surgery cannot be used as an alternative.
7. Transapical aortic valve replacement(TA-AVR)
Currently, more than 30 companies work in the
development of stent-fixed valves. Two devices have been
The TA-AVR is performed during general anesthesia.
introduced into clinical practice for sutureless transcatheter
Initially one-lung ventilation was instituted using a double-
AVR, ie, the CoreValve Revalving System (CRS™;
lumen tube, but this approach has been abandoned. A left
CoreValve, Inc., Irvine, CA, USA) and the Edwards-Sapien
anterolateral intercostal incision is used to expose the LV
valve (Edwards Lifesciences, Inc., Irvine, CA, USA).
apex and the pericardium is incised and retained. In
The CoreValve aortic valve prosthesis consists of a
addition, temporary epicardial ventricular pacing wires are
trileaflet bioprosthetic porcine pericardial tissue valve
placed. With the heart continuously beating, the apex is
mounted and sutured in a self-expanding nitinol stent.
punctured and the aortic valve passed in antegrade fashion
Nitinol, a nickel-titanium alloy, is a shape memory metal.
using a soft guidewire. A superstiff guidewire is inserted
The balloon expandable Edwards-Sapien valve is con-
and positioned across the aortic arch and anchored in the
structed from a tubular slotted stainless steel stent with an
descending aorta. A balloon valvuloplasty catheter is
attached bovine pericardial trileaflet valve.
positioned using fluoroscopic and/or TEE guidance. A
Both valves have received CE mark approval (consumer
valvuloplasty is performed to optimize the valve area
safety certification of the European Union) for transfemoral
for device placement. The balloon catheter is withdrawn
implantation, while for the transapical approach only the
and a 33-French transapical delivery sheath is inserted
Edwards Sapien valve has been approved.
followed by the valve. After de-airing and proper
H. Heinze et al.
A. Schematic drawing of the transfemoral and transapical approach for aortic valve replacement and retrograde positioning of the
catheter-mounted valve. B. Dilatation of the device dilatation with a balloon. C. Correct positioning at the end of the procedure. D. Devicepositioning and dilatation using an antegrade transapical approach with an introducer through the left ventricular apex. (Reproduced withpermission of Edwards Lifesciences, Inc., Irvine, CA, USA).
positioning, the valve is implanted during ventricular rapid
positioning and function have been verified, the myocar-
pacing (D). Sometimes repeated dilatations are
dium is closed using sutures placed at the outset and the
necessary to minimize paravalvular leakage. After correct
thorax is closed.
Anesthesia for percutaneous aortic valve replacement
Fluoroscopy time is usually less than 20 minutes, with
AVR may increase bleeding problems and may be life-
procedure time around 180 minutes .
threatening in the event that conversion to conventional on-
The transapical technique is considered safer in patients
pump AVR is indicated.
with severe peripheral vascular disease or increased risk of
Postprocedural care in patients after TF-AVR or TA-AVR
stroke as fewer aortic manipulations are necessary.
differs from care given after conventional surgical AVR.
During both procedures, the anesthesiologist monitors
While postoperative patients undergoing AVR with CPB are
hemodynamics, especially during balloon valvuloplasty and
often hypovolemic and show a typical post-CPB inflamma-
device deployment, as they might not recover immediately
tory response with decreased systemic vascular resistance,
after cessation of rapid pacing. New or increased aortic
leading to the need for relatively high amounts of fluids and
regurgitation might complicate the situation. In addition,
vasopressor therapy, patients after percutaneous AVR are at
ventricular fibrillation is possible and immediate electrical
risk of hypervolemia, especially if residual aortic regurgita-
defibrillation and cardiopulmonary resuscitation is necessary.
tion is present. Thus, adequate hemodynamic monitoring anddetailed hemodynamic care is necessary. Special attention torenal function is required, especially in patients with
8. Perioperative and postprocedural care
preoperatively reduced kidney function, as the nephrotoxiceffects of the contrast medium may aggravate the situation.
More than 1,200 transfemoral AVR for both CoreValve
For patients at risk, preventive strategies to reduce the
and Edwards-Sapien valves and about 450 transapical AVR
likelihood of contrast medium-induced nephropathy include
have been performed. As greater numbers of patients are
preprocedural and periprocedural IV hydration therapy and
treated, the number of complications presumably will
use of the lowest dose possible of low-osmolarity contrast
decrease. The physician responsible for periprocedural care
medium. The use of nephroprotective agents such as N-
should be aware of certain risks.
acetylcysteine or theophylline is controversial, but may be
During implantation, embolization of atherosclerotic
considered in certain patients Loop diuretics
plaques is possible due to pre-dilation and detachment or
increase renal injury after application of radiocontrast dye
fragmentation. Migration of the valve stent into the
these drugs should be used cautiously.
ascending aorta or the aortic arch is possible, with the need
Atrioventricular conduction blocks are a well-known
of conversion to standard surgery. Studies have reported a
complication of aortic valve surgery. It is noteworthy that
mortality rate of up to 15%, stroke at 0.4% to 4.6%, MI at
after transfemoral AVR and transapical AVR, blocks may
0.2% to 6.5%, and cardiac perforation at 0.3% to 1.8% after
develop up to one week post-procedure, necessitating
balloon valvuloplasty . Published short-term and mid-
permanent pacemaker insertion .
term results of percutaneous AVR and isolated conventionalAVR are summarized in .
During antegrade transfemoral AVR, where a transseptal
puncture is performed and the mitral valve is crossed using aballoon flotation catheter, there is a risk of tethering or trauma-tizing the anterior leaflet of the mitral valve. This situation
Transcutaneous AVR, whether using the transfemoral or
may lead to acute severe mitral regurgitation . The retro-
the transapical route, is an innovative approach. Anesthe-
grade approach avoids potential mitral leaflet complications.
siologists caring for these patients either during or after the
A severe complication shared by all three approaches is
procedure should have sound knowledge of the procedure
the obstruction of the coronary ostia with subsequent MI
and its risks and complications. As different specialties and
A special problem may be aortic regurgitation due to
personnel, including cardiac surgeons, cardiologists,
paravalvular leakages or inadequate device expansion.
anesthesiologists, OR nurses, and technicians have to work
Minor regurgitation immediately after insertion of the
together in unfamiliar surroundings, cooperation, collabora-
valve may be acceptable in patients with preserved
tion, and experience are of paramount interest for success.
ventricular function and it typically disappears after several
Before transcutaneous AVR may be recommended for a
hours. Moderate and high-grade regurgitation normally is
wider patient group, properly designed, prospective, ran-
treated with additional device dilatation. In case of severely
domized clinical trials comparing transfemoral AVR,
depressed LV function, TEE may underestimate the true
transapical AVR, and conventional surgical AVR are
severity of the situation and special emphasis regarding
necessary to determine long-term outcome.
systemic cardiopulmonary function is essential to rule outacute heart failure.
During transapical AVR, there is a constant risk of
systemic air embolism with catastrophic clinical conse-quences. Local bleeding problems at the catheter insertion
 Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons
site may require surgical repair. Anticoagulant loading
within structural heart disease. J Thorac Cardiovasc Surg 2006;132:
therapy with clopidogrel and aspirin during transfemoral
H. Heinze et al.
 Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation
 Walther T, Kempfert J, Borger MA, et al. Human minimally invasive
of artificial heart valves. Description of a new expandable aortic valve
off-pump valve-in-a-valve implantation. Ann Thorac Surg 2008;85:
and initial results with implantation by catheter technique in closed
chest pigs. Eur Heart J 1992;13:704-8.
 Zegdi R, Sleilaty G, Lafont A, Fabiani JN. Percutaneous aortic valve
 Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Transcatheter
replacement with the CoreValve prosthesis [Letter]. J Am Coll Cardiol
implantation of a bovine valve in pulmonary position: a lamb study.
 Heringlake M, Heinze H, Misfeld M, Klaus S, Bechtel M. Goal-
 Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter
directed hemodynamic optimization in high-risk cardiac surgery
implantation of an aortic valve prosthesis for calcific aortic stenosis:
patients: a tale from the past or a future obligation? Minerva Anestesiol
first human case description. Circulation 2002;106:3006-8.
 Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic
 Eltzschig HK, Rosenberger P, Löffler M, Fox JA, Aranki SF, Shernan
stenosis with the percutaneous heart valve: mid-term follow-up from
SK. Impact of intraoperative transesophageal echocardiography on
the initial feasibility studies: the French experience. J Am Coll Cardiol
surgical decisions in 12,566 patients undergoing cardiac surgery. Ann
Thorac Surg 2008;85:845-52.
 Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve
 Fassl J, Walther T, Birnbaum J, Mohr FW, Ender J. Transesophageal
replacement for severe aortic stenosis in high-risk patients using the
echocardiographic monitoring during transapical aortic valve implan-
second-and current third-generation self-expanding CoreValve pros-
tation. Appl Cardiopulm Pathophysiol 2006;10:27-31.
thesis: device success and 30-day clinical outcome. J Am Coll Cardiol
 Hilberath JN, Shernan SK, Segal S, Smith B, Eltzschig HK. The
feasibility of epicardial echocardiography for measuring aortic valve
 Lichtenstein SV, Cheung A, Ye J, et al. Transapical transcatheter aortic
area by the continuity equation. Anesth Analg 2009;108:17-22.
valve implantation in humans: initial clinical experience. Circulation
 Rosenberger P, Shernan SK, Löffler M, et al. The influence of
epiaortic ultrasonography on intraoperative surgical management in
 Walther T, Chu MW, Mohr FW. Transcatheter aortic valve
6051 cardiac surgical patients. Ann Thorac Surg 2008;85:548-53.
implantation: time to expand? Curr Opin Cardiol 2008;23:111-6.
 Figulla HR, Cremer J, Walther T, et al. Position paper on catheter-
 Iung B. Management of the elderly patient with aortic stenosis. Heart
based aortic valve surgery. Der Kardiologe 2009;3:199-206.
 Sauren B, Zickmann B, Gerckens U, Grube E, Felderhoff T, Iversen S.
 Kolh P, Kerzmann A, Honore C, Comte L, Limet R. Aortic valve
TOE support for percutaneous transluminal implantation of a self-
surgery in octogenarians: predictive factors for operative and long-
expanding valve prothesis for interventional treatment of aortic valve
term results. Eur J Cardiothorac Surg 2007;31:600-6.
stenosis. Appl Cardiopulm Pathophysiol 2006;10:24-6.
 Grube E, Laborde JC, Gerckens U, et al. Percutaneous implantation of
 Zierer A, Wimmer-Greinecker G, Martens S, Moritz A, Doss M. The
the CoreValve self-expanding valve prosthesis in high-risk patients
transapical approach for aortic valve implantation. J Thorac Cardio-
with aortic valve disease: the Siegburg first-in-man study. Circulation
vasc Surg 2008;136:948-53.
 Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic
 Walther T, Falk V, Kempfert J, et al. Transapical minimally invasive
valvuloplasty in adults: failure of procedure to improve long-term
aortic valve implantation: the initial 50 patients. Eur J Cardiothorac
survival. J Am Coll Cardiol 1995;26:1522-8.
 Hanzel GS, O'Neill WW. Complications of percutaneous aortic valve
 Rosengart TK, Feldman T, Borger MA, et al; American Heart
replacement: experience with the Cribier-Edwards percutaneous heart
Association Council on Cardiovascular Surgery and Anesthesia;
valve. Eurointervention Suppl 2006;1(Suppl A):A3-8.
American Heart Association Council on Clinical Cardiology;
 Flecher EM, Curry JW, Joudinaud TM, Kegel CL, Weber PA, Duran
Functional Genomics and Translational Biology Interdisciplinary
CM. Coronary flow obstruction in percutaneous aortic valve
Working Group; Quality of Care and Outcomes Research Interdisci-
replacement. An in vitro study. Eur J Cardiothorac Surg 2007;32:
plinary Working Group. Percutaneous and minimally invasive valve
procedures: a scientific statement from the American Heart Associ-
 Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of
ation Council on Cardiovascular Surgery and Anesthesia, Council on
N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised
Clinical Cardiology, Functional Genomics and Translational Biology
clustering to resolve heterogeneity. BMC Med 2007;5:32.
Interdisciplinary Working Group, and Quality of Care and Outcomes
 Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-
Research Interdisciplinary Working Group. Circulation 2008;117:
analysis: effectiveness of drugs for preventing contrast-induced
nephropathy. Ann Intern Med 2008;148:284-94.
 Walther T, Falk V, Dewey T, et al. Valve-in-a-valve concept for
 Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline,
transcatheter minimally invasive repeat xenograft implantation. J Am
mannitol, and furosemide to prevent acute decreases in renal function
Coll Cardiol 2007;50:56-60.
induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
Contents lists available at Ageing Research Reviews Vitamin E supplementation and lifespan in model organisms I.M.A. Ernst , K. Pallauf , J.K. Bendall , L. Paulsen , S. Nikolai , P. Huebbe , T. Roeder , G. Rimbach a Institute of Human Nutrition and Food Science, Christian-Albrechts-University Kiel, Hermann-Rodewald-Straße 6-8, D-24118 Kiel, Germany b Zoological Institute, Zoophysiology II, Christian-Albrechts-University Kiel, Olshausenstraße 40, D-24098 Kiel, Germany
Schweizerische Vereinigung für Offizielles Mitteilungsblatt der Schweizerischen Vereinigung für Parapsychologie 7. Jg / Nr. 37 – Juli/August 2007 Parapsychologie, Brückfeldstr. 19, Tel. 031 302 00 33, Fax 031 302 00 50 Ich bin eine Seele Internet: www.svpp.ch E-Mail: email@example.com Liebe Leserinnen, liebe Leser, Ich habe einen Körper